Gilead's Hepatitis C Treatment Sofosbuvir Gets European Commission Nod
Gilead Sciences’ Sofosbuvir, a hepatitis C treatment potentially faster and more effective than current therapies, has been approved by the European Commission. The European Commission approval predicates marketing rights for Gilead in all European Union countries including European Economic Area countries Iceland, Norway, and Liechtenstein.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news
More News: Hepatitis | Hepatitis C | Iceland Health | Liechtenstein Health | Marketing | Pharmaceuticals